2016
Rapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study
Colman RE, Anderson J, Lemmer D, Lehmkuhl E, Georghiou SB, Heaton H, Wiggins K, Gillece JD, Schupp JM, Catanzaro DG, Crudu V, Cohen T, Rodwell TC, Engelthaler DM. Rapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study. Journal Of Clinical Microbiology 2016, 54: 2058-2067. PMID: 27225403, PMCID: PMC4963505, DOI: 10.1128/jcm.00535-16.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleGenotyping TechniquesHigh-Throughput Nucleotide SequencingHumansMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisPharmaceutical PreparationsPilot ProjectsSequence Analysis, DNASpecimen HandlingSputumTime FactorsYoung AdultConceptsDrug-resistant tuberculosisPatient sputum samplesDrug resistance profilesSputum samplesDrug-resistant Mycobacterium tuberculosis isolatesPhenotypic drug susceptibility testing resultsDrug susceptibility testing resultsEvidence-based treatment plansResistance profilesMajor global health concernRapid drug susceptibility testingMycobacterium tuberculosis isolatesNext-generation sequencingClinical samplesAmplification of resistanceDrug susceptibility testingTargeted Next-Generation SequencingMycobacterium tuberculosis DNAGlobal health concernSusceptibility testing resultsSame clinical samplePhenotypic DSTInfectious causesTreatment outcomesTuberculosis isolates
2010
Development of Extensively Drug-resistant Tuberculosis during Multidrug-resistant Tuberculosis Treatment
Shin SS, Keshavjee S, Gelmanova IY, Atwood S, Franke MF, Mishustin SP, Strelis AK, Andreev YG, Pasechnikov AD, Barnashov A, Tonkel TP, Cohen T. Development of Extensively Drug-resistant Tuberculosis during Multidrug-resistant Tuberculosis Treatment. American Journal Of Respiratory And Critical Care Medicine 2010, 182: 426-432. PMID: 20413630, PMCID: PMC2921603, DOI: 10.1164/rccm.200911-1768oc.Peer-Reviewed Original ResearchConceptsMDR-TB treatmentXDR-TBDrug-resistant tuberculosisMultidrug-resistant (MDR) TBMDR-TB treatment programmeExtensively Drug-Resistant TuberculosisMultidrug-resistant tuberculosis treatmentCox proportional hazards modelDevelopment of XDRMDR-TB therapyTB treatment servicesAmplification of resistanceProportional hazards modelThreefold increaseMDR-TBCavitary lesionsConsecutive patientsAppropriate therapyClinical outcomesTreatment adherenceTuberculosis treatmentInjectable antibioticsTimely initiationPrescribed drugsRetrospective analysis